Japan-based Nipro has signed an agreement to acquire US-based medical device company Infraredx in order to expand its intravascular imaging solutions.

Infraredx is committed to advancing the diagnosis and management of coronary artery disease worldwide.

The acquisition will combine global and local expertise to deliver better intravascular imaging solutions, as well as expand a global vascular portfolio to the US.

“We look forward to bringing together the two companies to deliver the best of medicine and innovation.”

Nipro provides products and technologies for a wide range of fields including artificial organs, circulatory devices, test/diagnostic agents, injection/infusion solutions, ethical pharmaceuticals and medical glass products.

The transaction will allow Nipro to improve its expertise in near infrared spectroscopy (NIRS) and intravascular ultrasound, in addition to introducing its cardiovascular product line in the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The agreement will help to continue Infraredx’s mission to empower interventional cardiologists with advanced imaging tools required to predict heart attacks and prevent them.

Nipro president Yoshihiko Sano said: “Company founder James E Muller, MD, and the Infraredx management team have empowered interventional cardiologists with the NIRS-IVUS imaging system, which is approved to detect the lipid core plaques that cause most heart attacks.

“Nipro and Infraredx share a strong patient centered focus and the combination of the companies’ global portfolio and cardiovascular expertise will help us deliver the most comprehensive imaging solution available to change how cardiovascular disease is managed.

“We look forward to bringing together the two companies to deliver the best of medicine and innovation.”

Subject to certain conditions, the acquisition is expected to be completed in October this year.

In March, Infraredx introduced new advanced TVC imaging system and the Muller NIRS-IVUS catheter at the American College of Cardiology’s 2015 Annual Scientific Meeting in San Diego.

The company developed FDA cleared advanced TVC imaging system to identify lipid core plaques (LCPs), which complicate stenting procedures and are suspected to cause most heart attacks.